Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
